<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990271</url>
  </required_header>
  <id_info>
    <org_study_id>V2.3</org_study_id>
    <nct_id>NCT04990271</nct_id>
  </id_info>
  <brief_title>A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma</brief_title>
  <official_title>A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multi-center, open single-arm Phase II clinical trial is designed to&#xD;
      investigate the efficacy and safety of intravenous chemotherapy combined with Conbercept&#xD;
      intravitreal injection in the treatment of retinoblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the 1-year ocular salvage rate of intravenous chemotherapy combined with Conbercept intravitreal injection in the treatment of retinoblastoma</measure>
    <time_frame>1 year</time_frame>
    <description>12-month ocular salvage rate: calculate the number and percentage of subjects who reach 12-month ocular salvage rate, and use the exact probability method to estimate 95% CI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Conbercept intravitreal Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept ophthalmic injection</intervention_name>
    <description>Monthly injection of Conbercept from 0~5 months</description>
    <arm_group_label>Conbercept intravitreal Injection</arm_group_label>
    <other_name>KH902</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient's guardian signs an informed consent form and is willing to receive&#xD;
             follow-up according to the schedule of the trial;&#xD;
&#xD;
          2. Children of more than 3 months and under 5 years of age who have not received any&#xD;
             anti-cancer treatment;&#xD;
&#xD;
          3. The target eye must meet the following requirements:&#xD;
&#xD;
             Clinically diagnosed as monocular retinoblastoma; According to the IIRC diagnostic&#xD;
             criteria, the treatment eye is classified as Group E stage without clinical high-risk&#xD;
             factors (Table 1); No refractive medium turbidity and/or pupillary abnormalities that&#xD;
             affect the fundus examination; IOP≤21mmHg.&#xD;
&#xD;
          4. Sufficient organ function at baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with any of the following eye conditions:&#xD;
&#xD;
          1. Patients diagnosed as stage E retinoblastoma in one eye, but with high-risk factors:&#xD;
             neovascular glaucoma; refractive interstitial opacity caused by anterior chamber,&#xD;
             vitreous or subretinal hemorrhage; tumor invasion of optic nerve posterior to the&#xD;
             cribriform plate and choroid (range of diameter&gt; 2 mm), sclera, and anterior chamber;&#xD;
&#xD;
          2. Treatment-naïve pediatric patients;&#xD;
&#xD;
        Patients with any of the following systemic diseases:&#xD;
&#xD;
          1. With a history of allergies or have allergic reactions to fluorescein sodium, with a&#xD;
             history of allergies to protein products for treatment or diagnosis, and have allergic&#xD;
             reactions to two or more drugs and/or non-drug factors, or suffering from allergic&#xD;
             diseases;&#xD;
&#xD;
          2. Low birth weight children, and severely growth-stunted children;&#xD;
&#xD;
          3. Children who need systemic treatment for other system diseases;&#xD;
&#xD;
          4. Any condition that should be excluded from the study in the opinion of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xianqun Fan</last_name>
    <phone>13901696788</phone>
    <email>fanxq@sjtu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junyang Zhao</last_name>
      <phone>18601196456</phone>
      <email>zhaojunyang@163.com</email>
    </contact>
    <investigator>
      <last_name>Mei Jin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Children's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiantao Sun</last_name>
      <phone>18239966755</phone>
      <email>sunxt38019896@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuebing Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuang Sun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lihui Xu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Wu</last_name>
      <phone>13971110611</phone>
      <email>154957611@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yunyun Zhou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital Of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jia Tan</last_name>
      <phone>13875860564</phone>
      <email>jasmintj@126.com</email>
    </contact>
    <investigator>
      <last_name>Sha Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianqun Fan</last_name>
      <phone>139 0169 6788</phone>
      <email>fanxq@sjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Renbing Jia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiayan Fan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinoblastoma</keyword>
  <keyword>Conbercept</keyword>
  <keyword>VEC Intravenous Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

